Treatment Resistance Following Anti-cancer Therapies

Background: Development of new cancer treatments requires better understanding of why tumors develop resistance to standard-of-care (SOC) therapies. However, post-progression tumor biopsies are not routinely collected, limiting the tissue available to characterize mechanisms of treatment resistance. The TRANSLATE clinical study is specifically designed to address these critical gaps. Trial design: TRANSLATE is a global, multicenter, translational study designed to collect and compare archival pre-treatment tumor tissue with paired de novo tumor and blood samples obtained following disease progression on SOC therapies, targeting therapeutically important areas of cancer biology. Eligible Tumor Type and Most Recent SOC Therapy: * Non-small-cell lung and Anti-PD-1/-L1 monotherapy * Non-small-cell lung and Anti-PD-1/-L1 + platinum * Clear cell renal cell carcinoma and Anti-PD-1/-L1 monotherapy * Clear cell renal cell carcinoma and Doublet anti-PD-1/-L1 + anti-CTLA-4 * Clear cell renal cell carcinoma and Pembrolizumab + axitinib * Clear cell renal cell carcinoma and Avelumab + axitinib * HR+ HER2- breast and Palbociclib + hormonal therapy * germline mutated BRCA breast and Olaparib or talazoparib monotherapy * Castration-resistant prostate and Enzalutamide * Castration-resistant prostate and Abiraterone + prednisone Eligibility criteria include adults with locally advanced or metastatic tumors; radiographic evidence of progressive disease during the most recent SOC regimen; sufficient archival tumor tissue; and a post-progression tumor lesion that is safely accessible for a new biopsy. The results from clinical NGS panel testing may help inform subsequent treatment plan or identification of relevant interventional clinical trials. Patients are enrolled after disease progression on SOC and before change in treatment and participate in 3 study visits within approximately 3 months. Next-generation sequencing results from analysis of tumor tissue and blood will be returned to the study physician and patient for review at a subsequent study visit within this timeframe. The primary endpoint is the change in frequency of gene alterations between pre-treatment and post-progression tumor biopsies. Secondary endpoints address prioritized scientific hypotheses specific to each target area of biology and indication. Primary data will be publicly available after the study to support further research. Sponsored by Pfizer Inc.; EudraCT: 2018-003612-45.